References
- Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716–23
- Munkholm P, Langholz E, Nielsen O H, Davidsen M, Binder V. Incidence and prevalence of Crohn's disease in the County of Copenhagen, 1962–87: a sixfold increase in incidence. Scand J Gastroenterol 1992; 27: 609–14
- Bishop Y M, Fienberg S, Holland PW. Models for measuring change. Contingency tables and Markov models. Discrete multivariate analysis. Theory in practice. MIT Press, Boston 1971; 257–9
- Siegel S, Castellan NJ. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill 1988
- Malchow H, Ewe K, Brandes J W, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's disease study (ECCDS): results on drug treatment. Gastroenterology 1984; 86: 249–66
- Summers R W, Switz D M, Sessions J T, Becktel J M, Best W R, Kern F, et al. National Cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979; 77: 847–69
- Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M. The Italian IBD study group. Oral 5–aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363–8
- Gendre J-P, Mary J-Y, Florent C, Modigliani R, Colombel J-F, Soulé J-C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435–9
- Singleton J W, Hanauer S B, Gitnick G L, Peppercorn M A, Robinson M G, Wruble L D, et al. Mesalamine capsules for treatment of active Crohn's disease: results of a 16–week trial. Gastroenterology 1993; 104: 1293–301
- Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin®) after radical resection for Crohn's disease. Scand J Gastroenterol 1976; 11: 651–6
- Brynskov J, Freund L, Rasmussen S N, Lauritsen K, Schaffalitzky O, Williams N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active Crohn's disease. N Engl J Med 1989; 321: 845–50
- Mekhjian H S, Switz D M, Melnyk C S, Rankin G B, Brooks RK. Clinical features and natural history of Crohn's disease. Gastroenterology 1979; 77: 898–906
- Sachar D B, Wolfson D M, Greenstein A J, Goldberg J, Styczynski R, Janowitz HD. Risk factors for postoperative recurrence of Crohn's disease. Gastroenterology 1983; 85: 917–21
- Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956–63
- Halme L EH. Results of surgical treatment of patients with Crohn's disease. Ann Chir Gynaecol 1992; 81: 277–83
- Gazzard B G, Price H L, Libby G W, Dawson AM. The social toll of Crohn's disease. Br Med J 1978; 2: 1117–9
- Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease—based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146–50
- Mayberry M K, Probert C, Srivastava E, Rhodes J, Mayberry JF. Preceived discrimination in education and employment by people with Crohn's disease: a case control study of educational achievement and employment. Gut 1992; 33: 312–4
- Scirensen V Z, Olsen B G, Binder V. Life prospects and quality of life in patients with Crohn's disease. Gut 1987; 28: 382–5